Lorus Therapeutics Reports Third Quarter Results for Fiscal 2014
Marketwire - Thu Apr 10, 3:17PM CDT
Lorus Therapeutics Inc. (TSX: LOR) (Lorus"
Lorus Therapeutics To Host Third Quarter 2014 Financial Results Conference Call and Webcast
Marketwire - Tue Apr 08, 3:31PM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced it intends to release financial results for the quarter ended February 28, 2014, on Thursday, April 10, 2014 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. EDT to discuss the financial results.
Lorus Therapeutics Presents Preclinical Data on LOR-253 at American Association for Cancer Research Annual Meeting 2014
Marketwire - Tue Apr 08, 3:01PM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced the presentation of preclinical data for LOR-253, the company's lead anti-cancer agent, at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, CA. Lorus researchers demonstrated the ability of LOR-253 to induce cell death, or apoptosis, in blood cancer cell lines, including Acute Myeloid Leukemia (AML) cells, in vitro and concluded that the studies support further evaluation of LOR-253 as a potential therapy for AML and other hematologic cancers.
Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2014
Marketwire - Fri Apr 04, 6:01AM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced it will present preclinical data for LOR-253 in acute myeloid leukemia (AML) and other hematologic cancers at the American Association for Cancer Research (AACR) Annual Meeting 2014, to be held at the San Diego Convention Center in San Diego, CA, April 5-9, 2014.
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Marketwire - Thu Mar 27, 4:01PM CDT
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company"
IIROC Trade Resumption - LOR (all issues)
CNW Group - Thu Mar 27, 10:15AM CDT
Trading resumes in:
IIROC Trading Halt - LOR
CNW Group - Wed Mar 26, 2:38PM CDT
The following issues have been halted by IIROC:
Lorus Therapeutics Announces the Departure of Its President and Chief Operating Officer
Marketwire - Tue Mar 18, 7:24PM CDT
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company"
Lorus Therapeutics to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 6:02AM CST
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will present at the 26th Annual ROTH Conference at 3:00 p.m. PT on Tuesday, March 11th, 2014, in Dana Point, CA. Dr. Rice will provide a corporate overview of the Company's strategic direction including plans to develop Lorus' lead clinical agent LOR-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
Lorus Therapeutics to Present at the RBC Capital Markets 2014 Global Healthcare Conference
Marketwire - Mon Feb 24, 6:01AM CST
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will present at the RBC Capital Markets 2014 Global Healthcare Conference on Wednesday, February 26th, 2014, at 3:05 p.m. ET at the New York Palace Hotel in New York City. Dr. Rice will provide a corporate overview of the Company's strategic direction including plans to develop Lorus' lead clinical agent LOR-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
Lorus Therapeutics to Present at Biotech Showcase(TM) 2014
Marketwire - Mon Jan 13, 6:01AM CST
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will be presenting at Biotech Showcase 2014 on Wednesday, January 15, 2014, 4:30 pm PST at the Parc 55 Wyndham, San Francisco.
Lorus Therapeutics Inc. Announces Exercise in Full of Over-Allotment Option in Connection With Public Offering of Common Shares
Marketwire - Wed Jan 08, 8:29AM CST
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company"